Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2009 - 2025)

Alnylam Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $71.6 million for Q4 2025.

• Quarterly Share-based Compensation rose 141.86% year-over-year to $71.6 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $338.4 million (up 1743.09% YoY) and the FY2025 annual result came in at $348.2 million, up 3640.84% from the prior year.
• Share-based Compensation was $71.6 million for Q4 2025 at Alnylam Pharmaceuticals, down from $268.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $268.1 million in Q3 2025 and bottomed at -$171.1 million in Q4 2024.
• A 5-year average of $48.8 million and a median of $42.4 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 507.51% — and 2025, when it jumped 1169.51%.
• Alnylam Pharmaceuticals' Share-based Compensation stood at $44.6 million in 2021, then decreased by 4.07% to $42.8 million in 2022, then slipped by 1.81% to $42.0 million in 2023, then tumbled by 507.51% to -$171.1 million in 2024, then surged by 141.86% to $71.6 million in 2025.
• Business Quant data shows ALNY's Share-based Compensation at $71.6 million in Q4 2025, $268.1 million in Q3 2025, and -$1.3 million in Q2 2025.